Literature DB >> 32251515

PRDM16 suppresses HIF-targeted gene expression in kidney cancer.

Anirban Kundu1, Hyeyoung Nam1, Sandeep Shelar1, Darshan S Chandrashekar2, Garrett Brinkley1, Suman Karki1, Tanecia Mitchell1, Carolina B Livi3, Phillip Buckhaults4, Richard Kirkman1, Yawen Tang5, Glenn C Rowe5, Shi Wei2,6, Sooryanarayana Varambally2,6, Sunil Sudarshan1,6,7.   

Abstract

Analysis of transcriptomic data demonstrates extensive epigenetic gene silencing of the transcription factor PRDM16 in renal cancer. We show that restoration of PRDM16 in RCC cells suppresses in vivo tumor growth. RNaseq analysis reveals that PRDM16 imparts a predominantly repressive effect on the RCC transcriptome including suppression of the gene encoding semaphorin 5B (SEMA5B). SEMA5B is a HIF target gene highly expressed in RCC that promotes in vivo tumor growth. Functional studies demonstrate that PRDM16's repressive properties, mediated by physical interaction with the transcriptional corepressors C-terminal binding proteins (CtBP1/2), are required for suppression of both SEMA5B expression and in vivo tumor growth. Finally, we show that reconstitution of RCC cells with a PRDM16 mutant unable to bind CtBPs nullifies PRDM16's effects on both SEMA5B repression and tumor growth suppression. Collectively, our data uncover a novel epigenetic basis by which HIF target gene expression is amplified in kidney cancer and a new mechanism by which PRDM16 exerts its tumor suppressive effects.
© 2020 Kundu et al.

Entities:  

Year:  2020        PMID: 32251515     DOI: 10.1084/jem.20191005

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  8 in total

1.  Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes.

Authors:  Anna Julia Wiecek; Daniel Hadar Jacobson; Wojciech Lason; Maria Secrier
Journal:  Front Cell Dev Biol       Date:  2021-07-09

Review 2.  PRDM16 Regulating Adipocyte Transformation and Thermogenesis: A Promising Therapeutic Target for Obesity and Diabetes.

Authors:  Na Jiang; Ming Yang; Yachun Han; Hao Zhao; Lin Sun
Journal:  Front Pharmacol       Date:  2022-04-08       Impact factor: 5.988

3.  Analysis of m6A RNA Methylation-Related Genes in Liver Hepatocellular Carcinoma and Their Correlation with Survival.

Authors:  Yong Li; Dandan Qi; Baoli Zhu; Xin Ye
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

4.  Identification of Novel MeCP2 Cancer-Associated Target Genes and Post-Translational Modifications.

Authors:  Isabel Castro-Piedras; David Vartak; Monica Sharma; Somnath Pandey; Laura Casas; Deborah Molehin; Fahmida Rasha; Mohamed Fokar; Jacob Nichols; Sharilyn Almodovar; Rakhshanda Layeequr Rahman; Kevin Pruitt
Journal:  Front Oncol       Date:  2020-12-10       Impact factor: 6.244

5.  MECOM/PRDM3 and PRDM16 Serve as Prognostic-Related Biomarkers and Are Correlated With Immune Cell Infiltration in Lung Adenocarcinoma.

Authors:  Meng Li; Hui Ren; Yanpeng Zhang; Na Liu; Meng Fan; Ke Wang; Tian Yang; Mingwei Chen; Puyu Shi
Journal:  Front Oncol       Date:  2022-01-31       Impact factor: 6.244

6.  Prognostic and Diagnostic Values of Semaphorin 5B and Its Correlation With Tumor-Infiltrating Immune Cells in Kidney Renal Clear-Cell Carcinoma.

Authors:  Junping Ding; Shubin Zhao; Xianhua Chen; Changjun Luo; Jinjian Peng; Jiantan Zhu; Yongqi Shen; Zhou Luo; Jianlin Chen
Journal:  Front Genet       Date:  2022-04-11       Impact factor: 4.772

Review 7.  The evolving view of thermogenic fat and its implications in cancer and metabolic diseases.

Authors:  Xinpeng Yin; Yuan Chen; Rexiati Ruze; Ruiyuan Xu; Jianlu Song; Chengcheng Wang; Qiang Xu
Journal:  Signal Transduct Target Ther       Date:  2022-09-16

8.  Integrated Analysis of the Roles of RNA Binding Proteins and Their Prognostic Value in Clear Cell Renal Cell Carcinoma.

Authors:  Bowen Wang; Haoran Zhao; Shaobin Ni; Beichen Ding
Journal:  J Healthc Eng       Date:  2021-06-30       Impact factor: 2.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.